| 1 | surrogate | 2,220 |
| 2 | prespecified | 1,481 |
| 3 | predefined | 1,445 |
| 4 | predetermined | 713 |
| 5 | pre-specified | 646 |
| 6 | proxy | 426 |
| 7 | pre-defined | 339 |
| 8 | preplanned | 178 |
| 9 | preset | 142 |
| 10 | nuisance | 109 |
| 11 | pre-determined | 107 |
| 12 | protocol-defined | 99 |
| 13 | pre-planned | 86 |
| 14 | radiopaque | 82 |
| 15 | protocol-specified | 56 |
| 16 | pre-established | 53 |
| 17 | fiducial | 52 |
| 18 | pre-set | 38 |
| 19 | pre-selected | 37 |
| 20 | week-12 | 30 |
| 21 | radio-opaque | 26 |
| 22 | preestablished | 25 |
| 23 | pre-stated | 14 |
| 24 | selectable | 13 |
| 25 | prestated | 12 |
| 26 | gi-high | 10 |
| 27 | bacteroidales | 9 |
| 28 | analysis.the | 8 |
| 29 | non-prespecified | 8 |
| 30 | cb-cpt/mt | 7 |
| 31 | model-derived | 7 |
| 32 | client-specific | 6 |
| 33 | figurative | 6 |
| 34 | maastricht-amsterdam | 6 |
| 35 | treatment-selection | 6 |
| 36 | ndart1-3 | 5 |
| 37 | noncentrality | 5 |
| 38 | pan-neuronal | 5 |
| 39 | whopes | 5 |
| 40 | 5.5-cm | 4 |
| 41 | assay-specific | 4 |
| 42 | cmt4 | 4 |
| 43 | csulgie | 4 |
| 44 | database-specific | 4 |
| 45 | flack | 4 |
| 46 | nursing-sensitive | 4 |
| 47 | one-recall-interval-fits-all | 4 |
| 48 | progression-based | 4 |
| 49 | remap | 4 |
| 50 | survival-based | 4 |
| 51 | appropriate-use | 3 |
| 52 | eosinophil-negative | 3 |
| 53 | eosinophil-positive | 3 |
| 54 | hyper-reflective | 3 |
| 55 | inclusion/ | 3 |
| 56 | investigator-derived | 3 |
| 57 | ll-37-induced | 3 |
| 58 | no-drug | 3 |
| 59 | noti | 3 |
| 60 | parasporal | 3 |
| 61 | pre-agreed | 3 |
| 62 | radioopaque | 3 |
| 63 | railroad | 3 |
| 64 | random-effects-based | 3 |
| 65 | solid-fluid | 3 |
| 66 | species-diagnostic | 3 |
| 67 | sub-organismal | 3 |
| 68 | week.the | 3 |
| 69 | 1-os | 2 |
| 70 | 2-os | 2 |
| 71 | accp/sccm | 2 |
| 72 | age/sex-specific | 2 |
| 73 | anxious-depression | 2 |
| 74 | baseline-defined | 2 |
| 75 | bone-implanted | 2 |
| 76 | disease/intervention-specific | 2 |
| 77 | double-screening | 2 |
| 78 | er+veher2-ve | 2 |
| 79 | gh-sensitive | 2 |
| 80 | high-reversibility | 2 |
| 81 | hplc-derived | 2 |
| 82 | less-stringent | 2 |
| 83 | marker-defined | 2 |
| 84 | micromorphologic | 2 |
| 85 | mortality/survival | 2 |
| 86 | multi-vd | 2 |
| 87 | non-behaviorist | 2 |
| 88 | non-oropharynx | 2 |
| 89 | nonalbumin | 2 |
| 90 | noninternist | 2 |
| 91 | nyha-iv | 2 |
| 92 | polyglutamation | 2 |
| 93 | pound20,000 | 2 |
| 94 | ppi-responsive | 2 |
| 95 | preinclusion | 2 |
| 96 | protocol-stipulated | 2 |
| 97 | re-therapy | 2 |
| 98 | restenosis-test | 2 |
| 99 | section.the | 2 |
| 100 | subrogate | 2 |
| 101 | ≥2/3 | 2 |
| 102 | 'adding | 1 |
| 103 | 'illusory | 1 |
| 104 | 'otological | 1 |
| 105 | 'pistoia | 1 |
| 106 | -specified | 1 |
| 107 | 1,5-anhydroglucitol-a | 1 |
| 108 | 1-1-1 | 1 |
| 109 | 1.1-mg | 1 |
| 110 | 12-practice | 1 |
| 111 | 14-15,000 | 1 |
| 112 | 2.01-fold-higher | 1 |
| 113 | 3-khz | 1 |
| 114 | 3-path | 1 |
| 115 | 3.48-fold-higher | 1 |
| 116 | 5-member | 1 |
| 117 | 500-patient | 1 |
| 118 | 6-member | 1 |
| 119 | 6-protein | 1 |
| 120 | 66-patient | 1 |
| 121 | 93-patient | 1 |
| 122 | a2-165 | 1 |
| 123 | akt-positive | 1 |
| 124 | algorithmically-derived | 1 |
| 125 | auo-t. | 1 |
| 126 | baby.a | 1 |
| 127 | biocrudes | 1 |
| 128 | biotin-streptavidin-peroxidase | 1 |
| 129 | bmd-independent | 1 |
| 130 | book-supported | 1 |
| 131 | c-b60 | 1 |
| 132 | caution.adverse | 1 |
| 133 | cb1-receptor-dependent | 1 |
| 134 | chemotaxonomical | 1 |
| 135 | cinchona-based | 1 |
| 136 | comparisons.among | 1 |
| 137 | complaint.although | 1 |
| 138 | continuity-corrected | 1 |
| 139 | cpib-treated | 1 |
| 140 | cq-resistance | 1 |
| 141 | cy3-labeled | 1 |
| 142 | cyclotrichiid | 1 |
| 143 | dawes/redman | 1 |
| 144 | domesticforeign | 1 |
| 145 | double-head | 1 |
| 146 | dsm-iv™ | 1 |
| 147 | electroosmosis | 1 |
| 148 | exometm | 1 |
| 149 | g-luciferase | 1 |
| 150 | gipft | 1 |
| 151 | her1-3-negative | 1 |
| 152 | her1-3-positive | 1 |
| 153 | high-a1c | 1 |
| 154 | high-periostin | 1 |
| 155 | home.the | 1 |
| 156 | hr-positive/erbb2-positive | 1 |
| 157 | hypothesis-free | 1 |
| 158 | inter-spike | 1 |
| 159 | less.the | 1 |
| 160 | low-periostin | 1 |
| 161 | markers-proliferation | 1 |
| 162 | mesecnchymal | 1 |
| 163 | mgn-3+toce | 1 |
| 164 | mgn-3+toce+peit | 1 |
| 165 | microtubule-supported | 1 |
| 166 | mid-inclusion | 1 |
| 167 | molecular-defined | 1 |
| 168 | montelukast-responsive | 1 |
| 169 | multi-region | 1 |
| 170 | multiplcity-corrected | 1 |
| 171 | naa10p+sncg-prl-3- | 1 |
| 172 | naa10p-sncg+prl-3+ | 1 |
| 173 | neglected-only | 1 |
| 174 | nest-bound | 1 |
| 175 | neutrophil-activation | 1 |
| 176 | night-the | 1 |
| 177 | non-pediatrician | 1 |
| 178 | non-protocolised | 1 |
| 179 | non-subject | 1 |
| 180 | nonmathematic | 1 |
| 181 | of6 | 1 |
| 182 | oi-prostheses | 1 |
| 183 | one-dose-adjuvanted | 1 |
| 184 | over-60 | 1 |
| 185 | papg+/prsg+ | 1 |
| 186 | papovavirus-like | 1 |
| 187 | patient-profiling | 1 |
| 188 | pfs-based | 1 |
| 189 | pharmacokinetic-independent | 1 |
| 190 | phi29 | 1 |
| 191 | pk/tk | 1 |
| 192 | polyester-cotton | 1 |
| 193 | postsuspension | 1 |
| 194 | ppi-naive | 1 |
| 195 | preserved-ef | 1 |
| 196 | proteinuria-based | 1 |
| 197 | précised | 1 |
| 198 | psca-negative | 1 |
| 199 | psca-positive | 1 |
| 200 | pyridyltriazolopyridine-cyclodextrin | 1 |
| 201 | qilianyu | 1 |
| 202 | ra/oa | 1 |
| 203 | relative.the | 1 |
| 204 | reproducibility-based | 1 |
| 205 | revman-5 | 1 |
| 206 | risk-enrichment | 1 |
| 207 | rjm | 1 |
| 208 | screening-in | 1 |
| 209 | self-management/self-efficacy | 1 |
| 210 | severity.our | 1 |
| 211 | site-randomised | 1 |
| 212 | slc9a | 1 |
| 213 | slc9b | 1 |
| 214 | slc9c | 1 |
| 215 | statistical-meteorological | 1 |
| 216 | statistically-robust | 1 |
| 217 | sub-sensory | 1 |
| 218 | substantiveness | 1 |
| 219 | thaumarchaeotal | 1 |
| 220 | the* | 1 |
| 221 | thermal-injury-damage | 1 |
| 222 | tightly-optimized | 1 |
| 223 | time-temperature-load | 1 |
| 224 | transcedental | 1 |
| 225 | treatment-by-race/ethnic | 1 |
| 226 | tree-step | 1 |
| 227 | trichoscan™ | 1 |
| 228 | tritiated-water | 1 |
| 229 | turboionspray® | 1 |
| 230 | two-parallel-balanced-group | 1 |
| 231 | two-symptom | 1 |
| 232 | us-guidance | 1 |
| 233 | ushps | 1 |
| 234 | vaginal-health | 1 |
| 235 | variance-penalized | 1 |
| 236 | wholly-owned | 1 |
| 237 | worst-prognosis | 1 |
| 238 | year.an | 1 |
| 239 | yellow-browed | 1 |
| 240 | zero-dirichlet | 1 |
| 241 | £0·45 | 1 |
| 242 | α/β-galactosides | 1 |
| 1 | 'adding | 1 |
| 2 | 'illusory | 1 |
| 3 | 'otological | 1 |
| 4 | 'pistoia | 1 |
| 5 | -specified | 1 |
| 6 | 1,5-anhydroglucitol-a | 1 |
| 7 | 1-1-1 | 1 |
| 8 | 1-os | 2 |
| 9 | 1.1-mg | 1 |
| 10 | 12-practice | 1 |
| 11 | 14-15,000 | 1 |
| 12 | 2-os | 2 |
| 13 | 2.01-fold-higher | 1 |
| 14 | 3-khz | 1 |
| 15 | 3-path | 1 |
| 16 | 3.48-fold-higher | 1 |
| 17 | 5-member | 1 |
| 18 | 5.5-cm | 4 |
| 19 | 500-patient | 1 |
| 20 | 6-member | 1 |
| 21 | 6-protein | 1 |
| 22 | 66-patient | 1 |
| 23 | 93-patient | 1 |
| 24 | a2-165 | 1 |
| 25 | accp/sccm | 2 |
| 26 | age/sex-specific | 2 |
| 27 | akt-positive | 1 |
| 28 | algorithmically-derived | 1 |
| 29 | analysis.the | 8 |
| 30 | anxious-depression | 2 |
| 31 | appropriate-use | 3 |
| 32 | assay-specific | 4 |
| 33 | auo-t. | 1 |
| 34 | baby.a | 1 |
| 35 | bacteroidales | 9 |
| 36 | baseline-defined | 2 |
| 37 | biocrudes | 1 |
| 38 | biotin-streptavidin-peroxidase | 1 |
| 39 | bmd-independent | 1 |
| 40 | bone-implanted | 2 |
| 41 | book-supported | 1 |
| 42 | c-b60 | 1 |
| 43 | caution.adverse | 1 |
| 44 | cb-cpt/mt | 7 |
| 45 | cb1-receptor-dependent | 1 |
| 46 | chemotaxonomical | 1 |
| 47 | cinchona-based | 1 |
| 48 | client-specific | 6 |
| 49 | cmt4 | 4 |
| 50 | comparisons.among | 1 |
| 51 | complaint.although | 1 |
| 52 | continuity-corrected | 1 |
| 53 | cpib-treated | 1 |
| 54 | cq-resistance | 1 |
| 55 | csulgie | 4 |
| 56 | cy3-labeled | 1 |
| 57 | cyclotrichiid | 1 |
| 58 | database-specific | 4 |
| 59 | dawes/redman | 1 |
| 60 | disease/intervention-specific | 2 |
| 61 | domesticforeign | 1 |
| 62 | double-head | 1 |
| 63 | double-screening | 2 |
| 64 | dsm-iv™ | 1 |
| 65 | electroosmosis | 1 |
| 66 | eosinophil-negative | 3 |
| 67 | eosinophil-positive | 3 |
| 68 | er+veher2-ve | 2 |
| 69 | exometm | 1 |
| 70 | fiducial | 52 |
| 71 | figurative | 6 |
| 72 | flack | 4 |
| 73 | g-luciferase | 1 |
| 74 | gh-sensitive | 2 |
| 75 | gi-high | 10 |
| 76 | gipft | 1 |
| 77 | her1-3-negative | 1 |
| 78 | her1-3-positive | 1 |
| 79 | high-a1c | 1 |
| 80 | high-periostin | 1 |
| 81 | high-reversibility | 2 |
| 82 | home.the | 1 |
| 83 | hplc-derived | 2 |
| 84 | hr-positive/erbb2-positive | 1 |
| 85 | hyper-reflective | 3 |
| 86 | hypothesis-free | 1 |
| 87 | inclusion/ | 3 |
| 88 | inter-spike | 1 |
| 89 | investigator-derived | 3 |
| 90 | less-stringent | 2 |
| 91 | less.the | 1 |
| 92 | ll-37-induced | 3 |
| 93 | low-periostin | 1 |
| 94 | maastricht-amsterdam | 6 |
| 95 | marker-defined | 2 |
| 96 | markers-proliferation | 1 |
| 97 | mesecnchymal | 1 |
| 98 | mgn-3+toce | 1 |
| 99 | mgn-3+toce+peit | 1 |
| 100 | micromorphologic | 2 |
| 101 | microtubule-supported | 1 |
| 102 | mid-inclusion | 1 |
| 103 | model-derived | 7 |
| 104 | molecular-defined | 1 |
| 105 | montelukast-responsive | 1 |
| 106 | mortality/survival | 2 |
| 107 | multi-region | 1 |
| 108 | multi-vd | 2 |
| 109 | multiplcity-corrected | 1 |
| 110 | naa10p+sncg-prl-3- | 1 |
| 111 | naa10p-sncg+prl-3+ | 1 |
| 112 | ndart1-3 | 5 |
| 113 | neglected-only | 1 |
| 114 | nest-bound | 1 |
| 115 | neutrophil-activation | 1 |
| 116 | night-the | 1 |
| 117 | no-drug | 3 |
| 118 | non-behaviorist | 2 |
| 119 | non-oropharynx | 2 |
| 120 | non-pediatrician | 1 |
| 121 | non-prespecified | 8 |
| 122 | non-protocolised | 1 |
| 123 | non-subject | 1 |
| 124 | nonalbumin | 2 |
| 125 | noncentrality | 5 |
| 126 | noninternist | 2 |
| 127 | nonmathematic | 1 |
| 128 | noti | 3 |
| 129 | nuisance | 109 |
| 130 | nursing-sensitive | 4 |
| 131 | nyha-iv | 2 |
| 132 | of6 | 1 |
| 133 | oi-prostheses | 1 |
| 134 | one-dose-adjuvanted | 1 |
| 135 | one-recall-interval-fits-all | 4 |
| 136 | over-60 | 1 |
| 137 | pan-neuronal | 5 |
| 138 | papg+/prsg+ | 1 |
| 139 | papovavirus-like | 1 |
| 140 | parasporal | 3 |
| 141 | patient-profiling | 1 |
| 142 | pfs-based | 1 |
| 143 | pharmacokinetic-independent | 1 |
| 144 | phi29 | 1 |
| 145 | pk/tk | 1 |
| 146 | polyester-cotton | 1 |
| 147 | polyglutamation | 2 |
| 148 | postsuspension | 1 |
| 149 | pound20,000 | 2 |
| 150 | ppi-naive | 1 |
| 151 | ppi-responsive | 2 |
| 152 | pre-agreed | 3 |
| 153 | pre-defined | 339 |
| 154 | pre-determined | 107 |
| 155 | pre-established | 53 |
| 156 | pre-planned | 86 |
| 157 | pre-selected | 37 |
| 158 | pre-set | 38 |
| 159 | pre-specified | 646 |
| 160 | pre-stated | 14 |
| 161 | predefined | 1,445 |
| 162 | predetermined | 713 |
| 163 | preestablished | 25 |
| 164 | preinclusion | 2 |
| 165 | preplanned | 178 |
| 166 | preserved-ef | 1 |
| 167 | preset | 142 |
| 168 | prespecified | 1,481 |
| 169 | prestated | 12 |
| 170 | progression-based | 4 |
| 171 | proteinuria-based | 1 |
| 172 | protocol-defined | 99 |
| 173 | protocol-specified | 56 |
| 174 | protocol-stipulated | 2 |
| 175 | proxy | 426 |
| 176 | précised | 1 |
| 177 | psca-negative | 1 |
| 178 | psca-positive | 1 |
| 179 | pyridyltriazolopyridine-cyclodextrin | 1 |
| 180 | qilianyu | 1 |
| 181 | ra/oa | 1 |
| 182 | radio-opaque | 26 |
| 183 | radioopaque | 3 |
| 184 | radiopaque | 82 |
| 185 | railroad | 3 |
| 186 | random-effects-based | 3 |
| 187 | re-therapy | 2 |
| 188 | relative.the | 1 |
| 189 | remap | 4 |
| 190 | reproducibility-based | 1 |
| 191 | restenosis-test | 2 |
| 192 | revman-5 | 1 |
| 193 | risk-enrichment | 1 |
| 194 | rjm | 1 |
| 195 | screening-in | 1 |
| 196 | section.the | 2 |
| 197 | selectable | 13 |
| 198 | self-management/self-efficacy | 1 |
| 199 | severity.our | 1 |
| 200 | site-randomised | 1 |
| 201 | slc9a | 1 |
| 202 | slc9b | 1 |
| 203 | slc9c | 1 |
| 204 | solid-fluid | 3 |
| 205 | species-diagnostic | 3 |
| 206 | statistical-meteorological | 1 |
| 207 | statistically-robust | 1 |
| 208 | sub-organismal | 3 |
| 209 | sub-sensory | 1 |
| 210 | subrogate | 2 |
| 211 | substantiveness | 1 |
| 212 | surrogate | 2,220 |
| 213 | survival-based | 4 |
| 214 | thaumarchaeotal | 1 |
| 215 | the* | 1 |
| 216 | thermal-injury-damage | 1 |
| 217 | tightly-optimized | 1 |
| 218 | time-temperature-load | 1 |
| 219 | transcedental | 1 |
| 220 | treatment-by-race/ethnic | 1 |
| 221 | treatment-selection | 6 |
| 222 | tree-step | 1 |
| 223 | trichoscan™ | 1 |
| 224 | tritiated-water | 1 |
| 225 | turboionspray® | 1 |
| 226 | two-parallel-balanced-group | 1 |
| 227 | two-symptom | 1 |
| 228 | us-guidance | 1 |
| 229 | ushps | 1 |
| 230 | vaginal-health | 1 |
| 231 | variance-penalized | 1 |
| 232 | week-12 | 30 |
| 233 | week.the | 3 |
| 234 | wholly-owned | 1 |
| 235 | whopes | 5 |
| 236 | worst-prognosis | 1 |
| 237 | year.an | 1 |
| 238 | yellow-browed | 1 |
| 239 | zero-dirichlet | 1 |
| 240 | £0·45 | 1 |
| 241 | α/β-galactosides | 1 |
| 242 | ≥2/3 | 2 |
| 1 | the* | 1 |
| 2 | naa10p-sncg+prl-3+ | 1 |
| 3 | papg+/prsg+ | 1 |
| 4 | naa10p+sncg-prl-3- | 1 |
| 5 | auo-t. | 1 |
| 6 | inclusion/ | 3 |
| 7 | pound20,000 | 2 |
| 8 | 14-15,000 | 1 |
| 9 | over-60 | 1 |
| 10 | c-b60 | 1 |
| 11 | 1-1-1 | 1 |
| 12 | week-12 | 30 |
| 13 | ndart1-3 | 5 |
| 14 | ≥2/3 | 2 |
| 15 | cmt4 | 4 |
| 16 | revman-5 | 1 |
| 17 | £0·45 | 1 |
| 18 | a2-165 | 1 |
| 19 | of6 | 1 |
| 20 | phi29 | 1 |
| 21 | 1,5-anhydroglucitol-a | 1 |
| 22 | baby.a | 1 |
| 23 | slc9a | 1 |
| 24 | 'pistoia | 1 |
| 25 | ra/oa | 1 |
| 26 | slc9b | 1 |
| 27 | high-a1c | 1 |
| 28 | slc9c | 1 |
| 29 | database-specific | 4 |
| 30 | disease/intervention-specific | 2 |
| 31 | client-specific | 6 |
| 32 | age/sex-specific | 2 |
| 33 | assay-specific | 4 |
| 34 | micromorphologic | 2 |
| 35 | treatment-by-race/ethnic | 1 |
| 36 | nonmathematic | 1 |
| 37 | species-diagnostic | 3 |
| 38 | double-head | 1 |
| 39 | time-temperature-load | 1 |
| 40 | railroad | 3 |
| 41 | ll-37-induced | 3 |
| 42 | pre-agreed | 3 |
| 43 | pre-established | 53 |
| 44 | preestablished | 25 |
| 45 | -specified | 1 |
| 46 | pre-specified | 646 |
| 47 | protocol-specified | 56 |
| 48 | prespecified | 1,481 |
| 49 | non-prespecified | 8 |
| 50 | cy3-labeled | 1 |
| 51 | baseline-defined | 2 |
| 52 | pre-defined | 339 |
| 53 | protocol-defined | 99 |
| 54 | molecular-defined | 1 |
| 55 | marker-defined | 2 |
| 56 | predefined | 1,445 |
| 57 | pre-determined | 107 |
| 58 | predetermined | 713 |
| 59 | pre-planned | 86 |
| 60 | preplanned | 178 |
| 61 | wholly-owned | 1 |
| 62 | proteinuria-based | 1 |
| 63 | cinchona-based | 1 |
| 64 | survival-based | 4 |
| 65 | progression-based | 4 |
| 66 | pfs-based | 1 |
| 67 | random-effects-based | 3 |
| 68 | reproducibility-based | 1 |
| 69 | précised | 1 |
| 70 | non-protocolised | 1 |
| 71 | site-randomised | 1 |
| 72 | cpib-treated | 1 |
| 73 | protocol-stipulated | 2 |
| 74 | pre-stated | 14 |
| 75 | prestated | 12 |
| 76 | pre-selected | 37 |
| 77 | multiplcity-corrected | 1 |
| 78 | continuity-corrected | 1 |
| 79 | bone-implanted | 2 |
| 80 | one-dose-adjuvanted | 1 |
| 81 | microtubule-supported | 1 |
| 82 | book-supported | 1 |
| 83 | hplc-derived | 2 |
| 84 | model-derived | 7 |
| 85 | investigator-derived | 3 |
| 86 | algorithmically-derived | 1 |
| 87 | yellow-browed | 1 |
| 88 | variance-penalized | 1 |
| 89 | tightly-optimized | 1 |
| 90 | cyclotrichiid | 1 |
| 91 | solid-fluid | 3 |
| 92 | nest-bound | 1 |
| 93 | multi-vd | 2 |
| 94 | 12-practice | 1 |
| 95 | us-guidance | 1 |
| 96 | nuisance | 109 |
| 97 | cq-resistance | 1 |
| 98 | mgn-3+toce | 1 |
| 99 | hypothesis-free | 1 |
| 100 | thermal-injury-damage | 1 |
| 101 | night-the | 1 |
| 102 | home.the | 1 |
| 103 | relative.the | 1 |
| 104 | week.the | 3 |
| 105 | section.the | 2 |
| 106 | analysis.the | 8 |
| 107 | less.the | 1 |
| 108 | csulgie | 4 |
| 109 | papovavirus-like | 1 |
| 110 | inter-spike | 1 |
| 111 | selectable | 13 |
| 112 | biotin-streptavidin-peroxidase | 1 |
| 113 | g-luciferase | 1 |
| 114 | caution.adverse | 1 |
| 115 | appropriate-use | 3 |
| 116 | subrogate | 2 |
| 117 | surrogate | 2,220 |
| 118 | radio-opaque | 26 |
| 119 | radiopaque | 82 |
| 120 | radioopaque | 3 |
| 121 | er+veher2-ve | 2 |
| 122 | ppi-naive | 1 |
| 123 | ppi-responsive | 2 |
| 124 | montelukast-responsive | 1 |
| 125 | her1-3-negative | 1 |
| 126 | psca-negative | 1 |
| 127 | eosinophil-negative | 3 |
| 128 | figurative | 6 |
| 129 | hyper-reflective | 3 |
| 130 | nursing-sensitive | 4 |
| 131 | gh-sensitive | 2 |
| 132 | hr-positive/erbb2-positive | 1 |
| 133 | her1-3-positive | 1 |
| 134 | psca-positive | 1 |
| 135 | eosinophil-positive | 3 |
| 136 | akt-positive | 1 |
| 137 | preserved-ef | 1 |
| 138 | 1.1-mg | 1 |
| 139 | 'adding | 1 |
| 140 | patient-profiling | 1 |
| 141 | double-screening | 2 |
| 142 | comparisons.among | 1 |
| 143 | no-drug | 3 |
| 144 | gi-high | 10 |
| 145 | complaint.although | 1 |
| 146 | 3-path | 1 |
| 147 | vaginal-health | 1 |
| 148 | noti | 3 |
| 149 | flack | 4 |
| 150 | pk/tk | 1 |
| 151 | statistical-meteorological | 1 |
| 152 | 'otological | 1 |
| 153 | chemotaxonomical | 1 |
| 154 | fiducial | 52 |
| 155 | sub-organismal | 3 |
| 156 | mesecnchymal | 1 |
| 157 | pan-neuronal | 5 |
| 158 | parasporal | 3 |
| 159 | transcedental | 1 |
| 160 | thaumarchaeotal | 1 |
| 161 | mortality/survival | 2 |
| 162 | one-recall-interval-fits-all | 4 |
| 163 | maastricht-amsterdam | 6 |
| 164 | 5.5-cm | 4 |
| 165 | accp/sccm | 2 |
| 166 | rjm | 1 |
| 167 | two-symptom | 1 |
| 168 | exometm | 1 |
| 169 | year.an | 1 |
| 170 | non-pediatrician | 1 |
| 171 | dawes/redman | 1 |
| 172 | domesticforeign | 1 |
| 173 | screening-in | 1 |
| 174 | 6-protein | 1 |
| 175 | nonalbumin | 2 |
| 176 | pyridyltriazolopyridine-cyclodextrin | 1 |
| 177 | high-periostin | 1 |
| 178 | low-periostin | 1 |
| 179 | multi-region | 1 |
| 180 | postsuspension | 1 |
| 181 | anxious-depression | 2 |
| 182 | mid-inclusion | 1 |
| 183 | preinclusion | 2 |
| 184 | polyglutamation | 2 |
| 185 | markers-proliferation | 1 |
| 186 | neutrophil-activation | 1 |
| 187 | treatment-selection | 6 |
| 188 | polyester-cotton | 1 |
| 189 | remap | 4 |
| 190 | tree-step | 1 |
| 191 | two-parallel-balanced-group | 1 |
| 192 | 5-member | 1 |
| 193 | 6-member | 1 |
| 194 | 2.01-fold-higher | 1 |
| 195 | 3.48-fold-higher | 1 |
| 196 | tritiated-water | 1 |
| 197 | severity.our | 1 |
| 198 | α/β-galactosides | 1 |
| 199 | biocrudes | 1 |
| 200 | bacteroidales | 9 |
| 201 | whopes | 5 |
| 202 | oi-prostheses | 1 |
| 203 | electroosmosis | 1 |
| 204 | worst-prognosis | 1 |
| 205 | 1-os | 2 |
| 206 | 2-os | 2 |
| 207 | ushps | 1 |
| 208 | substantiveness | 1 |
| 209 | non-subject | 1 |
| 210 | zero-dirichlet | 1 |
| 211 | pre-set | 38 |
| 212 | preset | 142 |
| 213 | gipft | 1 |
| 214 | mgn-3+toce+peit | 1 |
| 215 | cb-cpt/mt | 7 |
| 216 | cb1-receptor-dependent | 1 |
| 217 | pharmacokinetic-independent | 1 |
| 218 | bmd-independent | 1 |
| 219 | less-stringent | 2 |
| 220 | 500-patient | 1 |
| 221 | 93-patient | 1 |
| 222 | 66-patient | 1 |
| 223 | risk-enrichment | 1 |
| 224 | restenosis-test | 2 |
| 225 | noninternist | 2 |
| 226 | non-behaviorist | 2 |
| 227 | statistically-robust | 1 |
| 228 | qilianyu | 1 |
| 229 | nyha-iv | 2 |
| 230 | non-oropharynx | 2 |
| 231 | self-management/self-efficacy | 1 |
| 232 | neglected-only | 1 |
| 233 | re-therapy | 2 |
| 234 | sub-sensory | 1 |
| 235 | 'illusory | 1 |
| 236 | noncentrality | 5 |
| 237 | high-reversibility | 2 |
| 238 | proxy | 426 |
| 239 | 3-khz | 1 |
| 240 | trichoscan™ | 1 |
| 241 | dsm-iv™ | 1 |
| 242 | turboionspray® | 1 |